RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP; FRA:P6P2) has formulated a strategic plan for 2017 through 2019 focused on maturing its assets through three distinct pillars.
They included commercializing the company’s dermal injector; R&D to enhance clinical efficacy, optimize manufacturing, strengthen its intellectual property portfolio; and preparing and launching Phase 2 clinical trials.
The plan includes several key milestones anticipated to be part of the company’s next 30 months, including:
- building and testing the commercial-grade prototypes of RepliCel’s next-generation dermal injector;
- preparing the RCI-02 device for marketing approval in Europe;
- executing an application-focused commercialization agreement for RCI-02 with a multi-national partner;
- launching and executing a molecular marker study anticipated to add significant value to the company’s intellectual property, manufacturing technologies, and the enhancement of clinical efficacy;
- completing ongoing research related to the manufacture of dermal sheath cup cells as a precursor to Phase 2 clinical trials of RCH-01;
- and preparing for Phase 2 clinical studies of the RCT-01 (tendinopathy) and RCS-01 (skin aging) clinical programs.
“Given the near-term commercial status of our dermal injector development and the nature of the discussions underway, we remain confident we will secure a revenue-generating, commercialization partnership for this asset next year,” president and CEO, Lee Buckler, said in a statement.
In addition, he said the company is currently engaged in a number of early-stage partnership and collaboration discussions for each of its cell therapy programs.
“While we have already commenced planning preparation for our next-phase clinical trials, these discussions may influence how we prioritize and finance these studies,” he added.
